ATE429925T1 - Methoden und pharmazeutische zusammensetzungen zur wundheilung - Google Patents

Methoden und pharmazeutische zusammensetzungen zur wundheilung

Info

Publication number
ATE429925T1
ATE429925T1 AT01963344T AT01963344T ATE429925T1 AT E429925 T1 ATE429925 T1 AT E429925T1 AT 01963344 T AT01963344 T AT 01963344T AT 01963344 T AT01963344 T AT 01963344T AT E429925 T1 ATE429925 T1 AT E429925T1
Authority
AT
Austria
Prior art keywords
methods
pharmaceutical compositions
wound healing
pharmaceutical composition
wound
Prior art date
Application number
AT01963344T
Other languages
English (en)
Inventor
Tamar Tennenbaum
Sanford Sampson
Toshio Kuroki
Addy Alt
Shlomzion Shen
Original Assignee
Univ Bar Ilan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bar Ilan filed Critical Univ Bar Ilan
Application granted granted Critical
Publication of ATE429925T1 publication Critical patent/ATE429925T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C12N5/0629—Keratinocytes; Whole skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/33—Insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT01963344T 2000-07-31 2001-07-23 Methoden und pharmazeutische zusammensetzungen zur wundheilung ATE429925T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62997000A 2000-07-31 2000-07-31
PCT/IL2001/000675 WO2002009639A2 (en) 2000-07-31 2001-07-23 Methods and pharmaceutical compositions for healing wounds

Publications (1)

Publication Number Publication Date
ATE429925T1 true ATE429925T1 (de) 2009-05-15

Family

ID=24525225

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01963344T ATE429925T1 (de) 2000-07-31 2001-07-23 Methoden und pharmazeutische zusammensetzungen zur wundheilung

Country Status (11)

Country Link
US (2) US7402571B2 (de)
EP (1) EP1383540B1 (de)
JP (2) JP2004536018A (de)
AT (1) ATE429925T1 (de)
AU (2) AU2001284364B2 (de)
CA (1) CA2416788A1 (de)
DE (1) DE60138572D1 (de)
DK (1) DK1383540T3 (de)
IL (1) IL154210A0 (de)
WO (1) WO2002009639A2 (de)
ZA (1) ZA200300708B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100129332A1 (en) * 2000-07-31 2010-05-27 Tamar Tennenbaum Methods and pharmaceutical compositions for healing wounds
US20030148924A1 (en) * 2002-07-09 2003-08-07 Tamar Tennenbaum Methods and pharmaceutical compositions of healing wounds
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
US20040037828A1 (en) * 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
US7402571B2 (en) 2000-07-31 2008-07-22 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
JP2005504533A (ja) * 2001-09-06 2005-02-17 ザ ジェネラル ホスピタル コーポレーション プロテインキナーゼＣλと関連のある疾患および状態の診断および治療のための方法
ZA200600235B (en) * 2003-07-15 2007-04-25 Healor Ltd 14 07 06 Methods and pharmaceutical compositions for healing wounds
DK1651161T3 (da) 2003-08-07 2012-01-30 Healor Ltd Farmaceutiske præparater og fremgangsmåder til at fremme sårheling
KR101240695B1 (ko) 2004-06-14 2013-03-11 바스프 뷰티 케어 솔루션즈 프랑스 에스에이에스 Ｐｔｈ 단편 함유 화장품 제제
EP2452686A3 (de) * 2005-08-29 2012-09-05 HealOr Ltd. Verfahren und Zusammensetzungen zur Vorbeugung und Behandlung von diabetischer und alternder Haut
FR2907683A1 (fr) * 2006-10-27 2008-05-02 De Potter Philippe Viseux Composition medicale pour cicatrisation des plaies et pansements permettant son application
EP2185184A2 (de) * 2007-07-30 2010-05-19 HealOr Ltd. Pharmazeutische zusammensetzung zur behandlung von wunden und entsprechende verfahren
WO2011083481A2 (en) 2010-01-11 2011-07-14 Healor Ltd. Method for treatment of inflammatory disease and disorder
US10183921B2 (en) * 2013-04-18 2019-01-22 Qbiotics Limited Methods and compositions for wound healing
CA2976096C (en) 2014-02-20 2023-03-14 University Of Notre Dame Du Lac Substituted 2-[(4-phenoxyphenyl)sulfonylmethyl]thiirane as selective matrix metalloproteinase inhibitors
US10357546B2 (en) 2014-09-19 2019-07-23 University Of Notre Dame Du Lac Acceleration of diabetic wound healing
US20180066327A1 (en) * 2015-03-13 2018-03-08 Joslin Diabetes Center, Inc. Methods to Accelerate Wound Healing in Diabetic Subjects
WO2017053659A1 (en) * 2015-09-23 2017-03-30 Khan Tapan K Methods for survival and rejuvenation of dermal fibroblasts using pkc activators
EP3595680A1 (de) 2017-03-17 2020-01-22 Rutgers, The State University of New Jersey Zusammensetzungen und verfahren zur wundheilung
CN115531415B (zh) * 2022-12-01 2023-03-28 山东大学 一种i-CS/HAp-NK复合体及其制备方法和应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US119914A (en) * 1871-10-17 Improvement in harness-trimmings
US4673649A (en) * 1983-07-15 1987-06-16 University Patents, Inc. Process and defined medium for growth of human epidermal keratinocyte cells
AU4292585A (en) 1984-04-30 1985-11-28 Trustees Of Columbia University In The City Of New York, The Topical treatment of diabetes with insulin and penetrant enhancer applied to the skin and covered by a patch
DE3674883D1 (de) * 1985-11-25 1990-11-15 Wako Pure Chem Ind Ltd Farbentwicklungsmethode in klinischen untersuchungen.
US4833257A (en) * 1986-07-28 1989-05-23 Arizona Board Of Regents Compositions of matter and methods of using same
JPS63303929A (ja) * 1987-06-04 1988-12-12 Kanji Izumi 創傷治療剤
US5700450A (en) 1988-03-30 1997-12-23 The Trustees Of Boston University Methods for enhancing melanin synthesis in melanocytes using diacyglycerols and uses thereof
US5137734A (en) 1989-03-22 1992-08-11 Dana Farber Cancer Institute Angiogenic monoglycerides
US5145679A (en) * 1989-10-05 1992-09-08 Hinson Joan B Topical emollient for prevention and treatment of circulatory induced lesions
US5423778A (en) 1989-12-14 1995-06-13 Elof Eriksson System and method for transplantation of cells
EP0580778B1 (de) 1991-04-19 1999-08-11 LDS Technologies, Inc. Konvertierbare mikroemulsionsverbindungen
JPH0543453A (ja) * 1991-08-20 1993-02-23 Sumitomo Pharmaceut Co Ltd 創傷治癒促進用局所用徐放性製剤
HUT67319A (en) * 1991-08-30 1995-03-28 Life Medical Sciences Inc Compositions for treating wounds
US5591709A (en) * 1991-08-30 1997-01-07 Life Medical Sciences, Inc. Compositions and methods for treating wounds
AU3062392A (en) * 1991-11-04 1993-06-07 Novo Nordisk A/S Pdgf gel formulation
DE4208552A1 (de) 1992-03-17 1993-09-23 Liedtke Pharmed Gmbh Topische arzneiformen mit insulin
CA2147810A1 (en) * 1994-04-25 1995-10-26 Susumu Yoshida Biologically active substance-secreting hybrid gel
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
JP3091113B2 (ja) * 1994-11-22 2000-09-25 科学技術振興事業団 生理活性物質分泌性のハイブリッド型ゲル
DE95907193T1 (de) 1994-12-29 2005-02-10 Savient Pharmaceuticals, Inc. Herstellung von humaninsulin
AUPN089295A0 (en) 1995-02-02 1995-03-02 International Diabetes Institute Treatment of diabetic neuropathy
AU1707497A (en) * 1996-01-23 1997-08-20 Rigel Pharmaceuticals, Inc. Methods for screening for transdominant intracellular effector peptides and rna molecules
US5869037A (en) 1996-06-26 1999-02-09 Cornell Research Foundation, Inc. Adenoviral-mediated gene transfer to adipocytes
GB9702943D0 (en) * 1997-02-13 1997-04-02 Univ Manchester Wound healing
JPH10265405A (ja) * 1997-03-19 1998-10-06 Masaaki Nanbara インスリン含有の皮膚外用製剤
WO1999018920A1 (en) 1997-10-16 1999-04-22 Deguang Zhu A new powerful cosmetic or pharmaceutical composition
AU3635099A (en) * 1997-12-15 1999-07-26 Beth Israel Deaconess Medical Center Methods and reagents for modulating cell motility
FR2773075B1 (fr) * 1997-12-31 2000-05-05 Cird Galderma Utilisation d'activateurs de ppar-gamma en dermatologie
WO1999034821A1 (en) * 1998-01-09 1999-07-15 Novo Nordisk A/S Stabilised insulin compositions
US6096288A (en) * 1998-10-12 2000-08-01 Mobil Oil Corporation Synthesis of the cubic mesoporous molecular sieve MCM-48
US6541447B1 (en) * 1999-09-01 2003-04-01 B & M Healthcare Technologies, Inc. Wound healing composition and method for use thereof
WO2001076650A1 (en) 2000-04-06 2001-10-18 University Technology Corporation Compositions and methods for promoting wound healing
US7402571B2 (en) 2000-07-31 2008-07-22 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
US6673603B2 (en) 2000-09-01 2004-01-06 Modex Therapeutiques, S.A. Cell paste comprising keratinocytes and fibroblasts
US20020119914A1 (en) 2000-12-26 2002-08-29 Deguang Zhu New uses of insulin and pancreatin
PT1365762E (pt) 2001-03-08 2008-11-27 Univ Kentucky Res Found Processo para aumentar os níveis de leptina utilizando compostos do ácido nicotínico

Also Published As

Publication number Publication date
AU8436401A (en) 2002-02-13
EP1383540A2 (de) 2004-01-28
US20030017969A1 (en) 2003-01-23
EP1383540A4 (de) 2004-06-30
DE60138572D1 (de) 2009-06-10
US20030144180A1 (en) 2003-07-31
US7402571B2 (en) 2008-07-22
IL154210A0 (en) 2003-07-31
CA2416788A1 (en) 2002-02-07
JP2011140505A (ja) 2011-07-21
JP2004536018A (ja) 2004-12-02
EP1383540B1 (de) 2009-04-29
ZA200300708B (en) 2005-02-23
AU2001284364B2 (en) 2006-09-28
HK1059738A1 (en) 2004-07-16
WO2002009639A3 (en) 2003-11-06
DK1383540T3 (da) 2009-08-24
JP5385321B2 (ja) 2014-01-08
WO2002009639A2 (en) 2002-02-07

Similar Documents

Publication Publication Date Title
ATE429925T1 (de) Methoden und pharmazeutische zusammensetzungen zur wundheilung
BG106095A (bg) Нови лекарствени състави на базата на антихолинергично активни съединения и бета-миметици
EE200400020A (et) Asendatud oksasolidinoonid kombineeritud raviks
SE0100568D0 (sv) Compounds
BRPI0418245B8 (pt) composto derivado de nitróxi de prostaglandina, processo para preparar dito composto, composição farmacêutica compreendendo dito composto e usos destes
EE200300033A (et) Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
DE60120648D1 (de) Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
CA2503810A1 (en) Therapeutic agent for fibromyalgia
WO2005007072A3 (en) Methods and pharmaceutical compositions for healing wounds
AU4258101A (en) Combination therapies with vascular damaging activity
AU2002214389A1 (en) Pharmaceutical composition containing honey for the treatment of wounds
SE0102440D0 (sv) New compound
SE0100566D0 (sv) Compounds
ATE319473T1 (de) Melagatran zur behandlung von entzündungen
AP1530A (en) Pharmaceutical composition for intramuscular injection containing loxoprofen.
HUP9901659A2 (hu) Flupirtin alkalmazása a hematopoetikus sejtrendszer károsodásával kapcsolatos megbetegedések megelőzésére és gyógyítására alkalmas gyógyszerkészítmény előállítására
SE0101692D0 (sv) Compounds
EE200200549A (et) Jagatud doosi teraapia veresooni kahjustava aktiivsusega
SE0000303D0 (sv) Novel compounds
SE9900190D0 (sv) New compounds
AR005724A1 (es) Derivados de ureido biologicamente activos utiles en el tratamiento de esclerosis multiple
DE50202865D1 (de) Herstellung reiner stereoisomere von tricyclo-[5.2.1.0(2.6) ]-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel
YU24603A (sh) Novi farmaceutski preparati koji sadrže epinastin i pseudoefedrin
NO20001846L (no) Nye farmasøytisk aktive forbindelser, deres fremstilling og anvendelse som ECE-inhibitorer

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1383540

Country of ref document: EP